Financial insights of GH

MyFinsight

For the quarter ending 2025-09-30, GH made $265,196K in revenue. -$92,725K in net income. Net profit margin of -34.96%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Revenue	265,196	232,088	203,471	191,476
Cost of revenue	93,587	81,205	74,723	-
Research and development expense	89,957	87,449	88,521	87,306
Sales and marketing expense	127,375	119,588	104,316	97,880
General and administrative expense	53,266	50,259	46,952	49,129
Cost of precision oncology testing	-	-	-	66,095
Cost of development services and other	-	-	-	8,394
Total costs and operating expenses	364,185	338,501	314,512	308,804
Loss from operations	-98,989	-106,413	-111,041	-117,328
Interest income	7,391	7,560	9,112	13,257
Interest expense	943	983	791	646
Other income (expense), net	-48	-25	7,851	-3,007
Loss before provision for income taxes	-92,589	-99,861	-94,869	-107,724
Provision for income taxes	136	38	290	30
Net loss	-92,725	-99,899	-95,159	-107,754

Net loss per share, basic (in usd per share)	-0.74	-0.8	-0.77	-0.88
Net loss per share, diluted (in usd per share)	-0.74	-0.8	-0.77	-0.88
Weighted-average shares used in computing net loss per share, basic (in shares)	124,807,000	124,114,000	123,871,000	123,051,000
Weighted-average shares used in computing net loss per share, diluted (in shares)	124,807,000	124,114,000	123,871,000	123,051,000